Literature DB >> 31223462

Do Zebrafish Obey Lipinski Rules?

Keith Long1, Stephen J Kostman2, Christian Fernandez1, James C Burnett3, Donna M Huryn1.   

Abstract

The use of zebrafish in whole organism phenotypic assays has become a valuable strategy throughout the drug discovery process. Zebrafish assays can be used not only to screen libraries of compounds at the earliest stages but also to evaluate advanced leads for their effects on specific biological pathways or for toxicity. However, when confronted with inactivity of a compound in a zebrafish assay, there are little data that can be used to judge if the compound is truly biologically inert or inactive due to a lack of permeability into the model organism. While medicinal chemistry principles suggest parameters that are predictive of human oral bioavailability, cellular permeability, and even bacterial permeability, there have been no such parameters developed for zebrafish absorption. To address this question, we compiled a set of 700 compounds reported in the literature to be active in zebrafish assays, evaluated their properties, and compared them to properties derived from a set of historical drugs and a set of recently approved oral drugs. While some properties overlap, the averages and 10th and 90th percentiles of molecular weight, octanol-water partition coefficient (logP), H-bond counts, and polar surface area for zebrafish-active compounds are statistically different from those of known drugs. This analysis should be useful to scientists interpreting structure-activity relationships based on data from zebrafish assays and help to inform the translation from fish to mammals.

Entities:  

Year:  2019        PMID: 31223462      PMCID: PMC6580538          DOI: 10.1021/acsmedchemlett.9b00063

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  20 in total

Review 1.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

Authors:  C A Lipinski; F Lombardo; B W Dominy; P J Feeney
Journal:  Adv Drug Deliv Rev       Date:  2001-03-01       Impact factor: 15.470

Review 2.  Bridging solubility between drug discovery and development.

Authors:  Li Di; Paul V Fish; Takashi Mano
Journal:  Drug Discov Today       Date:  2011-11-26       Impact factor: 7.851

3.  Identification and validation of bioactive small molecule target through phenotypic screening.

Authors:  Yoon Sun Cho; Ho Jeong Kwon
Journal:  Bioorg Med Chem       Date:  2011-11-20       Impact factor: 3.641

Review 4.  Advances in zebrafish high content and high throughput technologies.

Authors:  Filip Miscevic; Ori Rotstein; Xiao-Yan Wen
Journal:  Comb Chem High Throughput Screen       Date:  2012-08       Impact factor: 1.339

5.  ChemBioServer: a web-based pipeline for filtering, clustering and visualization of chemical compounds used in drug discovery.

Authors:  Emmanouil Athanasiadis; Zoe Cournia; George Spyrou
Journal:  Bioinformatics       Date:  2012-09-08       Impact factor: 6.937

6.  Molecular properties that influence the oral bioavailability of drug candidates.

Authors:  Daniel F Veber; Stephen R Johnson; Hung-Yuan Cheng; Brian R Smith; Keith W Ward; Kenneth D Kopple
Journal:  J Med Chem       Date:  2002-06-06       Impact factor: 7.446

Review 7.  Zebrafish assays for drug toxicity screening.

Authors:  Amy L Rubinstein
Journal:  Expert Opin Drug Metab Toxicol       Date:  2006-04       Impact factor: 4.481

8.  Small molecule screening in zebrafish: an in vivo approach to identifying new chemical tools and drug leads.

Authors:  Kerrie L Taylor; Nicola J Grant; Nicholas D Temperley; E Elizabeth Patton
Journal:  Cell Commun Signal       Date:  2010-06-12       Impact factor: 5.712

Review 9.  Zebrafish models for translational neuroscience research: from tank to bedside.

Authors:  Adam Michael Stewart; Oliver Braubach; Jan Spitsbergen; Robert Gerlai; Allan V Kalueff
Journal:  Trends Neurosci       Date:  2014-04-09       Impact factor: 13.837

10.  Abcb4 acts as multixenobiotic transporter and active barrier against chemical uptake in zebrafish (Danio rerio) embryos.

Authors:  Stephan Fischer; Nils Klüver; Kathleen Burkhardt-Medicke; Mirko Pietsch; Anne-Marie Schmidt; Peggy Wellner; Kristin Schirmer; Till Luckenbach
Journal:  BMC Biol       Date:  2013-06-17       Impact factor: 7.431

View more
  4 in total

1.  Validation of HDAC8 Inhibitors as Drug Discovery Starting Points to Treat Acute Kidney Injury.

Authors:  Keith Long; Zoe Vaughn; Michael David McDaniels; Sipak Joyasawal; Aneta Przepiorski; Emily Parasky; Veronika Sander; David Close; Paul A Johnston; Alan J Davidson; Mark de Caestecker; Neil A Hukriede; Donna M Huryn
Journal:  ACS Pharmacol Transl Sci       Date:  2022-03-16

Review 2.  The Dawn of a New Era in Drug Discovery? Drug Screening and the Increasing Biological Complexity of Testing Models.

Authors:  Wen-Jen Lin
Journal:  Chem Res Toxicol       Date:  2021-12-17       Impact factor: 3.973

3.  Spatiotemporal imaging and pharmacokinetics of fluorescent compounds in zebrafish eleuthero-embryos after different routes of administration.

Authors:  Marlly Guarin; Ruben Faelens; Arianna Giusti; Noémie De Croze; Marc Léonard; Deirdre Cabooter; Pieter Annaert; Peter de Witte; Annelii Ny
Journal:  Sci Rep       Date:  2021-06-09       Impact factor: 4.379

4.  Efficacy of Fenfluramine and Norfenfluramine Enantiomers and Various Antiepileptic Drugs in a Zebrafish Model of Dravet Syndrome.

Authors:  Jing Li; Maxim Nelis; Jo Sourbron; Daniëlle Copmans; Lieven Lagae; Deirdre Cabooter; Peter A M de Witte
Journal:  Neurochem Res       Date:  2021-05-26       Impact factor: 3.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.